Lista de obras - Jyothis T George - Dominio Público Uruguay

A survey in India of doctors' knowledge, attitudes and practice regarding telemedicine and e-health

artículo científico publicado en 2007

Brief Intervention in Type 1 diabetes - Education for Self-efficacy (BITES): Protocol for a randomised control trial to assess biophysical and psychological effectiveness

artículo científico publicado en 2007

Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease

artículo científico publicado en 2018

Clinical effectiveness of a brief educational intervention in Type 1 diabetes: results from the BITES (Brief Intervention in Type 1 diabetes, Education for Self-efficacy) trial

artículo científico

Consistent Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Irrespective of Diabetic Kidney Disease Categories - Insights from the EMPA-REG OUTCOME trial

artículo científico publicado en 2020

Diabetes Symposium

artículo científico publicado el 1 de enero de 2012

Differences in level of confidence in diabetes care between different groups of trainees: the TOPDOC diabetes study

artículo científico publicado en 2014

EMPAGLIFLOZIN IS ASSOCIATED WITH A LOWER RISK OF POST-ACUTE HEART FAILURE RE-HOSPITALIZATION AND MORTALITY: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL

artículo científico publicado en 2019

Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME

scientific article published on 11 September 2020

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial

scientific article published on 01 January 2019

Effect of a pocket-size tablet-dispensing device on glycaemic control in Type 2 diabetic patients

artículo científico publicado en 2007

Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial

artículo científico publicado en 2020

Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial

artículo científico publicado en 2020

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial

artículo científico publicado en 2017

Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure

artículo científico publicado en 2019

Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality

scientific article published on 01 March 2019

Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial

artículo científico publicado en 2020

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease

artículo científico publicado en 2017

Empagliflozin for Patients with Presumed Resistant Hypertension: a Post Hoc Analysis of the EMPA-REG OUTCOME Trial

scientific article published on 05 May 2020

Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®.

artículo científico publicado en 2018

Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline

artículo científico publicado en 2019

Equality, transparency, fairness for all.

artículo científico publicado en 2007

Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

scientific article published on 11 February 2019

Establishing pragmatic estimated glomerular filtration rate thresholds to guide metformin prescribing: careful assessment of risks and benefits is required

artículo científico publicado en 2008

Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism

artículo científico publicado en 2013

Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME

artículo científico publicado en 2020

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

artículo científico publicado en 2017

How does obesity affect fertility in men - and what are the treatment options?

artículo científico publicado en 2014

Hypothesis: kisspeptin mediates male hypogonadism in obesity and type 2 diabetes

artículo científico publicado en 2010

Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control

article

Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes

artículo científico publicado en 2019

Kisspeptin and the hypothalamic control of reproduction: lessons from the human

artículo científico publicado en 2012

Kisspeptin antagonists: unraveling the role of kisspeptin in reproductive physiology

scientific article published on 18 September 2010

Kisspeptin restores pulsatile LH secretion in patients with neurokinin B signaling deficiencies: physiological, pathophysiological and therapeutic implications

artículo científico publicado en 2012

Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men.

artículo científico publicado en 2011

Kisspeptin-10 stimulation of gonadotrophin secretion in women is modulated by sex steroid feedback

scientific article published on 05 September 2012

Lack of confidence among trainee doctors in the management of diabetes: the Trainees Own Perception of Delivery of Care (TOPDOC) Diabetes Study

artículo científico publicado en 2011

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

artículo científico publicado en 2019

Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial

scientific article published on 26 November 2020

Molecular clocks, type 2 diabetes and cardiovascular disease.

scientific article published on June 2008

Obstructive sleep apnoea; a rare cause of pseudophaeochromocytoma

artículo científico publicado en 2011

One-third of doctors completing specialist training in diabetes fail to secure a substantive consultant post: young Diabetologists' Forum Survey 2010.

artículo científico publicado en 2012

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high

artículo científico publicado en 2018

Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial

artículo científico publicado en 2019

Reversibility of fibrotic appearance of lungs with thyroxine replacement therapy in patients with severe hypothyroidism.

artículo científico publicado en 2009

SUN-LB015 Baseline Characteristics and Effects on CV and Kidney Outcomes with Linagliptin Versus Placebo, Across GFR Categories in CARMELINA.

artículo científico publicado en 2019

THE ASSOCIATION BETWEEN URIC ACID LEVELS AND CARDIORENAL OUTCOMES AND DEATH IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME

artículo científico publicado en 2019

THE INFLUENCE OF MICROVASCULAR DISEASE ON CARDIOVASCULAR EVENTS IN TYPE 2 DIABETES: A POST HOC ANALYSIS OF EMPA-REG OUTCOME

artículo científico publicado en 2019

The kisspeptin-GnRH pathway in human reproductive health and disease

artículo científico publicado en 2014

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

artículo científico publicado en 2018

The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors

artículo científico publicado en 2017

Training tomorrow's doctors in diabetes: self-reported confidence levels, practice and perceived training needs of post-graduate trainee doctors in the UK. A multi-centre survey

artículo científico publicado en 2008

Waist circumference in type 2 diabetes: is routine measurement helpful?

artículo científico publicado en 2007

Lista de obras de Jyothis T George

A survey in India of doctors' knowledge, attitudes and practice regarding telemedicine and e-health

Brief Intervention in Type 1 diabetes - Education for Self-efficacy (BITES): Protocol for a randomised control trial to assess biophysical and psychological effectiveness

Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease

Clinical effectiveness of a brief educational intervention in Type 1 diabetes: results from the BITES (Brief Intervention in Type 1 diabetes, Education for Self-efficacy) trial

Consistent Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Irrespective of Diabetic Kidney Disease Categories - Insights from the EMPA-REG OUTCOME trial

Diabetes Symposium

Differences in level of confidence in diabetes care between different groups of trainees: the TOPDOC diabetes study

EMPAGLIFLOZIN IS ASSOCIATED WITH A LOWER RISK OF POST-ACUTE HEART FAILURE RE-HOSPITALIZATION AND MORTALITY: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL

Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial

Effect of a pocket-size tablet-dispensing device on glycaemic control in Type 2 diabetic patients

Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial

Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial

Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure

Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality

Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease

Empagliflozin for Patients with Presumed Resistant Hypertension: a Post Hoc Analysis of the EMPA-REG OUTCOME Trial

Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®.

Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline

Equality, transparency, fairness for all.

Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

Establishing pragmatic estimated glomerular filtration rate thresholds to guide metformin prescribing: careful assessment of risks and benefits is required

Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism

Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

How does obesity affect fertility in men - and what are the treatment options?

Hypothesis: kisspeptin mediates male hypogonadism in obesity and type 2 diabetes

Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control

Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes

Kisspeptin and the hypothalamic control of reproduction: lessons from the human

Kisspeptin antagonists: unraveling the role of kisspeptin in reproductive physiology

Kisspeptin restores pulsatile LH secretion in patients with neurokinin B signaling deficiencies: physiological, pathophysiological and therapeutic implications

Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men.

Kisspeptin-10 stimulation of gonadotrophin secretion in women is modulated by sex steroid feedback

Lack of confidence among trainee doctors in the management of diabetes: the Trainees Own Perception of Delivery of Care (TOPDOC) Diabetes Study

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial

Molecular clocks, type 2 diabetes and cardiovascular disease.

Obstructive sleep apnoea; a rare cause of pseudophaeochromocytoma

One-third of doctors completing specialist training in diabetes fail to secure a substantive consultant post: young Diabetologists' Forum Survey 2010.

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high

Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial

Reversibility of fibrotic appearance of lungs with thyroxine replacement therapy in patients with severe hypothyroidism.

SUN-LB015 Baseline Characteristics and Effects on CV and Kidney Outcomes with Linagliptin Versus Placebo, Across GFR Categories in CARMELINA.

THE ASSOCIATION BETWEEN URIC ACID LEVELS AND CARDIORENAL OUTCOMES AND DEATH IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME

THE INFLUENCE OF MICROVASCULAR DISEASE ON CARDIOVASCULAR EVENTS IN TYPE 2 DIABETES: A POST HOC ANALYSIS OF EMPA-REG OUTCOME

The kisspeptin-GnRH pathway in human reproductive health and disease

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors

Training tomorrow's doctors in diabetes: self-reported confidence levels, practice and perceived training needs of post-graduate trainee doctors in the UK. A multi-centre survey

Waist circumference in type 2 diabetes: is routine measurement helpful?